Address Change

August 10, 2026 To, To, Listing/Compliance Department Listing/Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G-Block, Bandra-Kurla Complex, Mumbai – 400001 Bandra (E), Mumbai – 400051 BSE Scrip Code: 543998 NSE Symbol: VALIANTLAB Dear Sir/Madam, Subject: Outcome of Board Meeting held on August 10, 2026 Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) This is to inform you that the Board of Directors of Valiant Laboratories Limited (‘the Company’) at its meeting held today i.e. on Monday, August 10, 2026, has inter alia considered and approved the following: 1. Re-appointment of Managing Director Approved the re-appointment of Mr. Santosh Vora (DIN: 07633923) as the Managing Director of the Company, based on the recommendation of the Nomination and Remuneration Committee, for a further period of five (5) years with effect from February 06, 2027, and the remuneration payable to him during the said tenure, subject to the approval of the members of the Company by way of a Special Resolution at the ensuing Annual General Meeting and such other approvals as may be necessary. 2. Re-appointment of Independent Director Approved the re-appointment of Mrs. Sonal Vira (DIN: 09505883) as an Independent Director of the Company, based on the recommendation of the Nomination and Remuneration Committee for a second term of five (5) consecutive years with effect from February 16, 2027, subject to the approval of the members of the Company by way of a Special Resolution at the ensuing Annual General Meeting, and such other approvals as may be necessary. Further, Mrs. Sonal Vira has confirmed that she meets the criteria of independence as prescribed under the provisions of the Companies Act, 2013 and the Rules made thereunder, as well as the Listing Regulations. 3. Continuation of directorship of Non-Executive Non-Independent Director Approved and recommended the continuation of directorship of Mr. Shantilal Vora (DIN: 07633852), as a Non-Executive Non-Independent Director of the Company upon his attaining the age of 75 years, with effect from November 05, 2027, subject to the approval of the members of the Company by way of a Special Resolution at the ensuing Annual General Meeting, in terms of Regulation 17(1A) of the Listing Regulations. www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. T: 022-49717221/49712001/49717220 | E: investor@valiantlabs.in Further, Mr. Santosh Vora, Mrs. Sonal Vira and Mr. Shantilal Vora are not debarred from holding the office of Director by virtue of any Order passed by the Securities and Exchange Board of India or any other such authority. 4. Shifting of Registered Office of the Company Shifting of the Registered Office of the Company from 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080 to Plot No. L-13, L-28, L-28(Pt), L-29 & L-30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506, resulting in a change in jurisdiction from the Registrar of Companies, Mumbai-I to the Registrar of Companies, Mumbai-II (Navi Mumbai), subject to the approval of the members of the Company by way of a Special Resolution, the confirmation of the Regional Director, Western Region, Ministry of Corporate Affairs, and such other approvals as may be required. 5. Opening of a new Corporate Office of the Company Opening of a new Corporate Office of the Company at 701, Tower B, Embassy 247 Park, LBS Road, Vikhroli (West), Mumbai – 400083, from where the administrative, management, finance, secretarial and other corporate functions of the Company shall be carried out. 6. Additional investment in Valiant Advanced Sciences Private Limited ("VASPL") up to an amount not exceeding Rs. 60 Crore, by way of subscription to 1% Optionally Convertible Redeemable Preference Shares Approval for making further investment in Valiant Advanced Sciences Private Limited ("VASPL"), a wholly owned subsidiary of the Company, up to an aggregate amount not exceeding ₹60 Crore, by way of subscription to 1% Optionally Convertible Redeemable Preference Shares, in one or more tranches, subject to applicable laws and approvals, if any. The details as required under Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 (‘SEBI LODR Master Circular’) are enclosed herewith as “Annexure-A” (re- appointment of Directors and continuation of directorship) and “Annexure-B” (investment in VASPL). The Board Meeting commenced at 04:30 p.m. and concluded at 06:00 p.m. This intimation is also being uploaded on the Company’s website at www.valiantlabs.in. We request you to take the same on record. Thanking you, Yours faithfully, For Valiant Laboratories Limited Akshay Gangurde Company Secretary & Compliance Officer Encl: As above www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. T: 022-49717221/49712001/49717220 | E: investor@valiantlabs.in Annexure – A Details of re-appointment of Directors and continuation of directorship Sr. Particulars Disclosure 1 Name of Mrs. Sonal Vira Mr. Santosh Vora Mr. Shantilal Vora Director 2 Reason for Re-appointment of Mrs. Re-appointment of Mr. Continuation of change viz. Sonal Vira (DIN: Santosh Vora (DIN: directorship of Mr. appointment, 09505883) as an 07633923) as a Managing Shantilal Vora (DIN: reappointmen Independent Director of Director of the 07633852), as Non- t, resignation, the Company for a Company. Executive Non- removal, second term. Independent Director death or of the Company upon otherwise attaining the age of 75 years. 3 Date and Date of re-appointment Date of re-appointment Date of continuation – term of – Effective from – Effective from Effective from Appointment February 16, 2027, February 06, 2027, November 05, 2027, /Re- subject to the approval of subject to the approval of subject to the approval Appointment the members by way of a the members at the of the members by way Special Resolution at the ensuing AGM. of a Special Resolution ensuing AGM. at the ensuing AGM, in Term of re-appointment terms of Regulation Term of re-appointment – Five (5) consecutive 17(1A) of the Listing – Five (5) consecutive years, NOT liable to Regulations. years, NOT liable to retire by rotation. retire by rotation. Term – Continuation as a Non-Executive Non-Independent Director, liable to retire by rotation 4 Brief Mrs. Sonal Vira is a Mr. Santosh Vora holds a Mr. Shantilal Vora has Profile Commerce graduate bachelor’s degree in over 45 years of from the University of commerce with experience in the Mumbai and a specialization in chemical and Chartered Accountant Financial Markets from pharmaceutical from the ICAI. She has University of Mumbai industry. He over 15 years of and has also completed specialises in experience in corporate the Post Graduate developing new banking, having Programme in markets and handled clients across Management for Family customers, both for the the entire spectrum of Business from The Company’s existing the market, from large Indian School of products and for its domestic conglomerates Business (ISB), new business segments to multinational Hyderabad. He has over and has vast corporations and mid- 8 years of experience in experience in handling market companies. Her the chemical and the sales and skills include a sound pharmaceutical marketing of bulk understanding of drugs. His key areas of www.valiantlabs.in | CIN : L24299MH2021PLC365904 Registered Office: 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (W), Mumbai - 400080. T: 022-49717221/49712001/49717220 | E: investor@valiantlabs.in financial analysis and industry. He looks afte [Showing first 8,000 characters — download PDF for full document]